Prognosis of vasculitis associated myelodysplasia

C. Belizna(Centre National de la Recherche Scientifique), Norbert Ifrah(Inserm), Michael C. Royer(Université d'Angers), Jan Voswinkel(Sorbonne Université), L. Martin(Université d'Angers), J.F. Subra(Centre Hospitalier Universitaire d'Angers), Daniel Henrion(Centre National de la Recherche Scientifique), A. Ghali(Laboratoires d'Anjou (France)), Y. Le Corre(Université d'Angers), Gilles Rénier(Université d'Angers)
Autoimmunity Reviews
March 28, 2013
10.1016/j.autrev.2013.01.005
Cited by 10

Related Papers

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
|Clinical Pharmacology & Therapeutics|2010|363
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
|Blood|2013|357
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
|Blood|2013|286
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
|Blood|2007|252
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
|Blood|2010|196